Pulmonary/Respiratory Diseases | Preclinical Developments

Vicore Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Vicore Pharma's Drug Candidate VP01 Demonstrates Potential for Significant Benefit in Severe Pulmonary Hypertension

Lead Product(s): VP01

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: VP01

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

Administration of clinically relevant oral doses of VP01 in the so called Sugen-Hypoxia-induced pulmonary hypertension model in rats caused a significant and therapeutically meaningful reduction in pulmonary arterial pressure without affecting the systemic blood pressure.

Miragen Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

miRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate

Lead Product(s): MRG-229

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MRG-229

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

MRG-229 has demonstrated mechanistic biomarker regulation and antifibrotic activity in vitro using human model systems.

Bonus BioGroup

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Wize Pharma's Strategic Transaction Partner Bonus BioGroup to Present MesenCure Data

Lead Product(s): MesenCure

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 27, 2020

Details:

Treatment with MesenCure reduced fluid in the lungs by 47% compared to untreated subjects, and significantly increased blood lymphocyte counts, which play a key role in fighting viruses.

Windtree Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Windtree Therapeutics Announces Closing of $23 Million Public Offering Including Full Exercise of Over-Allotment Option

Lead Product(s): Sinapultide

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Ladenburg Thalmann & Co

Deal Size: $20.2 million Upfront Cash: Undisclosed

Deal Type: Public Offering May 22, 2020

Details:

Windtree intends to use the net proceeds from this offering to advance the study of KL4 surfactant to treat COVID-19 related lung injury; istaroxime acute heart failure phase 2b start-up activities;clinical development of AEROSURF;pre-clinical studies of SERCA2a activators.

Romanian National Institute of Infectious Diseases

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Diffusion Pharma and Romanian National Institute of Infectious Diseases Join Hands to Expand Clinical Trial Program of TSC for COVID-19

Lead Product(s): Transcrocetinate sodium

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Diffusion Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 20, 2020

Details:

Diffusion Pharma has entered into an agreement with the Romanian National Institute of Infectious Diseases to begin a clinical trial program to test Diffusion’s lead drug trans sodium crocetinate for the treatment of hospitalized COVID-19 patients with hypoxemia.

Bonus BioGroup

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Wize Pharma's Strategic Transaction Partner Bonus BioGroup Reports Successful Treatment of Acute Pneumonia in Preclinical COVID-19 Model

Lead Product(s): Activated mesenchymal stromal cells

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2020

Details:

Bonus reported that following treatment with MesenCure, the microscopic appearance of treated lungs was similar to healthy lungs, and a significant improvement in additional parameters was achieved.

Nabriva Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

CohBar To Target COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with its Apelin Receptor Agonist Peptides

Lead Product(s): CB5064 analogs

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2020

Details:

CohBar will test its CB5064 analogs in preclinical models of ARDS, to assess their potential as therapeutics for coronavirus disease 2019 (COVID-19) associated ARDS.

CohBar

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

CohBar’s Abstract for ATS 2020 International Conference Published in the American Journal of Respiratory and Critical Care Medicine

Lead Product(s): MBT2

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 01, 2020

Details:

CohBar’s poster will contain data on a family of novel analogs of a peptide encoded in mitochondrial DNA, demonstrating beneficial effects in mouse models of Idiopathic Pulmonary Fibrosis (IPF).

CohBar

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

CohBar Announces Acceptance of Late Breaking Abstract on its Antifibrotic Peptides

Lead Product(s): MBT2

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 14, 2020

Details:

The presentation highlights potential of MBT2 to Inhibit Fibrogenesis in Cultured Human Lung Cells and its efficacy in Mouse Models of Idiopathic Pulmonary Fibrosis (IPF).

SutroVax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia

Lead Product(s): SVX-24

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: RA Capital Management

Deal Size: $110.0 million Upfront Cash: Undisclosed

Deal Type: Series D Financing March 26, 2020

Details:

SutroVax has generated preclinical proof of concept versus the standard of care vaccines and intends to advance SVX-XP into the clinic as a future successor to SVX-24.

Find

Find Drugs for Pulmonary/Respiratory Diseases in Preclinical Development

Preclinical

Product Type

Companies

Vicore Pharma

Vicore Pharma's Drug Candidate VP01 Demonstrates Potential for Significant Benefit in Severe Pulmonary Hypertension

Miragen Therapeutics

miRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate

Bonus BioGroup

Wize Pharma's Strategic Transaction Partner Bonus BioGroup to Present MesenCure Data

Windtree Therapeutics

Windtree Therapeutics Announces Closing of $23 Million Public Offering Including Full Exercise of Over-Allotment Option

Romanian National Institute of Infectious Diseases

Diffusion Pharma and Romanian National Institute of Infectious Diseases Join Hands to Expand Clinical Trial Program of TSC for COVID-19

Bonus BioGroup

Wize Pharma's Strategic Transaction Partner Bonus BioGroup Reports Successful Treatment of Acute Pneumonia in Preclinical COVID-19 Model

Nabriva Therapeutics

CohBar To Target COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with its Apelin Receptor Agonist Peptides

CohBar

CohBar’s Abstract for ATS 2020 International Conference Published in the American Journal of Respiratory and Critical Care Medicine

CohBar

CohBar Announces Acceptance of Late Breaking Abstract on its Antifibrotic Peptides

SutroVax

SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia